PL2984108T3 - Przeciwciała anty s100a7 do leczenia i diagnozowania nowotworu - Google Patents

Przeciwciała anty s100a7 do leczenia i diagnozowania nowotworu

Info

Publication number
PL2984108T3
PL2984108T3 PL14723729T PL14723729T PL2984108T3 PL 2984108 T3 PL2984108 T3 PL 2984108T3 PL 14723729 T PL14723729 T PL 14723729T PL 14723729 T PL14723729 T PL 14723729T PL 2984108 T3 PL2984108 T3 PL 2984108T3
Authority
PL
Poland
Prior art keywords
antibodies
diagnosis
cancer
treatment
Prior art date
Application number
PL14723729T
Other languages
English (en)
Inventor
Míguez José Luis Hernández
Plana Jaume Adan
Escolà Josep Maria Martínez
Álvarez Marc Masa
Peypoch Ramon Messeguer
Prat Francesc Mitjans
Plaza Sheila Dakhel
Manzano Antonio Coll
VILLEGAS ROSA Mª HERVAS
Calpe Carme Calvis
García Laura Padilla
Navarro Lourdes Tatiana Roque
Ferrando Laura Barberà
Cañas Manuel Rivas
Original Assignee
Lykera Biomed, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lykera Biomed, S.A. filed Critical Lykera Biomed, S.A.
Publication of PL2984108T3 publication Critical patent/PL2984108T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL14723729T 2013-04-09 2014-04-09 Przeciwciała anty s100a7 do leczenia i diagnozowania nowotworu PL2984108T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382128 2013-04-09
PCT/EP2014/057213 WO2014167030A1 (en) 2013-04-09 2014-04-09 Anti-s100a7 antibodies for the treatment and diagnosis of cancer
EP14723729.1A EP2984108B1 (en) 2013-04-09 2014-04-09 Anti-s100a7 antibodies for the treatment and diagnosis of cancer

Publications (1)

Publication Number Publication Date
PL2984108T3 true PL2984108T3 (pl) 2017-12-29

Family

ID=48049929

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14723729T PL2984108T3 (pl) 2013-04-09 2014-04-09 Przeciwciała anty s100a7 do leczenia i diagnozowania nowotworu

Country Status (11)

Country Link
US (1) US9914768B2 (pl)
EP (1) EP2984108B1 (pl)
CN (1) CN105873950A (pl)
CY (1) CY1119430T1 (pl)
DK (1) DK2984108T3 (pl)
ES (1) ES2639227T3 (pl)
LT (1) LT2984108T (pl)
PL (1) PL2984108T3 (pl)
PT (1) PT2984108T (pl)
SM (1) SMT201700402T1 (pl)
WO (1) WO2014167030A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3430022B1 (en) * 2016-03-14 2020-03-11 Somalogic, Inc. Compounds and methods for the synthesis of 5-(n-protected-tryptaminocarboxyamide)-2'-deoxyuridine phosphoramidite for incorporation into a nucleic acid sequence
KR102645432B1 (ko) * 2016-03-28 2024-03-11 (주)아모레퍼시픽 피부 세포 분화 촉진용 조성물 및 피부 세포 분화 촉진 물질의 스크리닝 방법
CN106943594A (zh) * 2017-03-29 2017-07-14 西安交通大学 Psoriasin抗体和LL‑37抗体在制备防治银屑病的药物中的应用
EP4626474A2 (en) * 2022-12-02 2025-10-08 Ohio State Innovation Foundation S100a7 as a diagnostic marker and therapeutic target for disorders
WO2024180552A2 (en) * 2023-03-01 2024-09-06 Bountica Ltd. An eco-friendly, sustainable food preservative
CN119638830B (zh) * 2024-12-24 2025-11-14 武汉爱博泰克生物科技有限公司 针对人s100a7蛋白的抗体、抗体对和试剂盒及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
WO2003057159A2 (en) * 2001-12-31 2003-07-17 Dana-Farber Cancer Institute, Inc. Psoriasin expression by breast epithelial cells
US20100021472A1 (en) 2008-07-25 2010-01-28 Geetha Srikrishna Methods for diagnosing and treating cancer
SMT201900219T1 (it) 2010-06-14 2019-05-10 Lykera Biomed S A Anticorpi anti-s100a4 e relativi usi terapeutici

Also Published As

Publication number Publication date
LT2984108T (lt) 2017-11-10
CY1119430T1 (el) 2018-03-07
CN105873950A (zh) 2016-08-17
EP2984108A1 (en) 2016-02-17
DK2984108T3 (en) 2017-09-18
WO2014167030A1 (en) 2014-10-16
SMT201700402T1 (it) 2017-11-15
US20160289307A1 (en) 2016-10-06
EP2984108B1 (en) 2017-05-31
ES2639227T3 (es) 2017-10-25
US9914768B2 (en) 2018-03-13
PT2984108T (pt) 2017-09-19

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and preparations for the treatment of cancer
PL3033086T3 (pl) Terapia skojarzona do leczenia nowotworów złośliwych
HUE046674T2 (hu) B7-H1 elleni antitestek tumorok kezelésére
IL244884B (en) Antibodies conjugated against ly75 for cancer therapy
GB201413357D0 (en) Antibodies for treatment and diagnosis
PL3511004T3 (pl) Preparaty skojarzone do leczenia raka
PL3062790T3 (pl) Połączenia farmaceutyczne do leczenia raka
IL250507A0 (en) Anti-ck8 antibodies for use in cancer therapy
GB201500875D0 (en) Antibodies for treatment and diagnosis
IL245551A0 (en) Anti-matriptase antibodies for cancer treatment
PL2984108T3 (pl) Przeciwciała anty s100a7 do leczenia i diagnozowania nowotworu
EP2991650A4 (en) Methods for the treatment of cancer
IL255273A0 (en) igf-1r antibody and its use for cancer diagnosis
EP3089984A4 (en) NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES
ZA201707247B (en) Igf-1r antibody and its use for the diagnosis of cancer
EP3102940A4 (en) Anti-metalloprotease antibody for diagnosis and treatment of cancers
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
GB201309498D0 (en) Novel diagnosis and therapy
GB201301685D0 (en) Diagnosis and treatment of cancer
GB201302884D0 (en) Novel methods for diagnosis and therapy